136 related articles for article (PubMed ID: 38555576)
1. Application of CMV-IVIg as prophylaxis against cytomegalovirus reactivation in allogeneic hematopoietic stem cell transplantation patients.
Cui J; Zhou Y; Zhao K; Li X; Zhang H; Zhang X; Sun Y; Long B
Clin Transplant; 2024 Apr; 38(4):e15300. PubMed ID: 38555576
[TBL] [Abstract][Full Text] [Related]
2. A clinical study of lyophilized intravenous human immunoglobulin containing high-titer cytomegalovirus-neutralizing antibody for the treatment of cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation.
Zhang P; Yang D; Tian J; Feng S; Jiang E; Han M
Ann Palliat Med; 2021 May; 10(5):5533-5540. PubMed ID: 34107701
[TBL] [Abstract][Full Text] [Related]
3. Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis.
Włodarczyk M; Wieczorkiewicz-Kabut A; Białas K; Koclęga A; Noster I; Zielińska P; Helbig G
Turk J Haematol; 2024 Mar; 41(1):9-15. PubMed ID: 38345092
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II-IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group.
Kimura SI; Tamaki M; Okinaka K; Seo S; Uchida N; Igarashi A; Ozawa Y; Ikegame K; Eto T; Tanaka M; Shiratori S; Nakamae H; Sawa M; Kawakita T; Onizuka M; Fukuda T; Atsuta Y; Kanda Y; Nakasone H
Ann Hematol; 2021 Dec; 100(12):3029-3038. PubMed ID: 34490500
[TBL] [Abstract][Full Text] [Related]
7. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.
Dwabe S; Hsiao M; Ali A; Rodman J; Savitala-Damerla L; Nazaretyan S; Kimberly Schiff NP; Tam E; Ladha A; Woan K; Chaudhary P; Yaghmour G
Transpl Immunol; 2023 Feb; 76():101769. PubMed ID: 36464218
[TBL] [Abstract][Full Text] [Related]
8. The role of immunoglobulin prophylaxis for prevention of cytomegalovirus infection in pediatric hematopoietic stem cell transplantation recipients.
Goldstein G; Rutenberg TF; Mendelovich SL; Hutt D; Oikawa MT; Toren A; Bielorai B
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28087884
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus reactivation under pre-emptive therapy following allogeneic hematopoietic stem cell transplant: Pattern, survival, and risk factors in the Republic of Korea.
Kang KW; Jeon MJ; Yu ES; Kim DS; Lee BH; Lee SR; Choi CW; Park Y; Kim BS; Sung HJ
PLoS One; 2023; 18(9):e0291268. PubMed ID: 37703263
[TBL] [Abstract][Full Text] [Related]
10. Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients.
Camacho-Bydume C; Mauguen A; Rodriguez-Sanchez MI; Klein E; Kernan NA; Prockop S; Boelens JJ; Papanicolaou GA; Cancio M
Cytotherapy; 2022 Apr; 24(4):428-436. PubMed ID: 35042670
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review.
Jerry Teng CL; Wang PN; Chen YC; Ko BS
J Microbiol Immunol Infect; 2021 Jun; 54(3):341-348. PubMed ID: 33514495
[TBL] [Abstract][Full Text] [Related]
12. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Cytomegalovirus Specific Immunoglobulins to Reduce CMV Reactivation in Pediatric Hematopoietic Stem Cell Transplant Recipients.
Geurten C; Ghinai R; Munford H; Lawson S
J Pediatr Hematol Oncol; 2023 Jan; 45(1):e82-e86. PubMed ID: 36162011
[TBL] [Abstract][Full Text] [Related]
14. Negative Impact of Cytomegalovirus Reactivation on Survival in Adult Patients with Aplastic Anemia after an Allogeneic Hematopoietic Stem Cell Transplantation: A Report from Transplantation-Related Complication and Adult Aplastic Anemia Working Groups of the Japan Society for Hematopoietic Cell Transplantation.
Takenaka K; Onishi Y; Mori T; Hirakawa T; Tada Y; Uchida N; Kobayashi T; Kanda Y; Ozawa Y; Ota S; Iida H; Fukushima K; Kimua T; Fukuda T; Atsuta Y; Matsuto K; Yamazaki H; Nakasone H
Transplant Cell Ther; 2021 Jan; 27(1):82.e1-82.e8. PubMed ID: 33039517
[TBL] [Abstract][Full Text] [Related]
15. CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality.
Eberhardt KA; Jung V; Knops E; Heger E; Wirtz M; Steger G; Kaiser R; Affeldt P; Holtick U; Klein F; Scheid C; Di Cristanziano V
Bone Marrow Transplant; 2023 Jun; 58(6):639-646. PubMed ID: 36869190
[TBL] [Abstract][Full Text] [Related]
16. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
Liu LW; Yn A; Gao F; Olson M; Crain M; Abboud R; Westervelt P; Abboud C; Vij R; Stockerl-Goldstein K; Pusic I; Cashen AF; Schroeder MA
Transplant Cell Ther; 2022 Aug; 28(8):510.e1-510.e9. PubMed ID: 35598841
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation.
Sokos DR; Berger M; Lazarus HM
Biol Blood Marrow Transplant; 2002; 8(3):117-30. PubMed ID: 11939601
[TBL] [Abstract][Full Text] [Related]
18. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients.
Alexander BT; Hladnik LM; Augustin KM; Casabar E; McKinnon PS; Reichley RM; Ritchie DJ; Westervelt P; Dubberke ER
Pharmacotherapy; 2010 Jun; 30(6):554-61. PubMed ID: 20500045
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus reactivation after hematopoietic stem cell transplant with CMV-IG prophylaxis: A monocentric retrospective analysis.
Gilioli A; Messerotti A; Bresciani P; Cuoghi A; Pioli V; Colasante C; Bettelli F; Giusti D; Forghieri F; Potenza L; Donatelli F; Giubbolini R; Galassi L; Marasca R; Banchelli F; D'Amico R; Pecorari M; Gennari W; Trenti T; Comoli P; Luppi M; Narni F
J Med Virol; 2021 Nov; 93(11):6292-6300. PubMed ID: 33580523
[TBL] [Abstract][Full Text] [Related]
20. Letermovir Prophylaxis for CMV Reactivation in Allogeneic Stem Cell Recipients: A Retrospective Single Center Analysis.
Koch K; Osswald L; Miller I; Braitsch K; Götze K; Bassermann F; Herhaus P; Verbeek M
Anticancer Res; 2022 Nov; 42(11):5431-5441. PubMed ID: 36288861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
